The Department of Justice has named a private equity firm as a co-defendant in a False Claims Act complaint, along with one of its portfolio companies. DOJ alleges that the portfolio company paid illegal kickbacks related to compound drug prescriptions reimbursed by TRICARE in an effort to increase its ROI. The inclusion of a PE firm as a defendant could signal DOJ’s intention to hold private equity sponsors accountable for the noncompliance of their portfolio companies.
Regulations, Compliance, & Enforcement
Trending Now
Proposed DFARS Rule Could Require Disclosures and Mitigation Related to Foreign Ownership, Control, and Influence (FOCI) on Certain Unclassified Contracts • OMB Plans to Make IT Contract Data Collection Public, Per Federal CIO • The DOJ Wants Strong FCA Whistleblower Lawsuits From Data Miners • US Investors Warm to Ukrainian Defense Startups—But Export Laws Slow Cooperation • Virginia Expands Restrictions on Employee Non-Compete Agreements
DOJ Pursues PE Firm Based on Portfolio Company’s Alleged Payment of Kickbacks
Track False Claims Act cases, audit trends, and compliance best practices with our Compliance & Enforcement newsletter, delivering up-to-the-minute intelligence Monday–Saturday — Subscribe here.